{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:52:49Z","timestamp":1790117569474,"version":"4.0.1"},"reference-count":94,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>Highly efficacious, potentially curative gene therapies holds immense clinical promise, but also present complex challenges. At the time of regulatory approval and health technology assessment (HTA), evidence of efficacy and safety of gene therapies is often uncertain. In addition, research, development, and manufacturing costs, small pools of eligible patients, and the fact that many gene therapies are administered only once means that they frequently are associated with very high \u201cone-off\u201d price points. Although only a limited number of products have been brought to market globally, hundreds of clinical trials of gene therapies, including several of monogenetic neuromuscular diseases, are currently ongoing. Over time, as more and more conditions become amendable to gene therapy, the number of transformative, high-cost treatments is likely to increase considerably. For these reasons, concerns have been raised regarding the suitability of current health policy systems, including HTA frameworks, in ensuring appropriate access to these therapeutic innovations while simultaneously safeguarding value for taxpayers\u2019 money, as well as affordability and sustainability. This review provides a summary overview of current challenges and future perspectives of gene therapies for neuromuscular diseases from a health economic point of view.<\/jats:p>","DOI":"10.3233\/jnd-221540","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T04:51:25Z","timestamp":1667019085000},"page":"675-688","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-7151","authenticated-orcid":false,"given":"Erik","family":"Landfeldt","sequence":"first","affiliation":[{"name":"IQVIA, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsy020"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz131"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210678"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00190-9"},{"key":"ref005","unstructured":"United States Food and Drug Administration. ZOLGENSMA. Available from: https:\/\/www.fda.gov\/vaccinesblood-biologics\/zolgensma (accessed June 15, 2022)."},{"key":"ref006","unstructured":"European Medicines Agency. Zolgensma. Available from:  https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma (accessed June 20, 2022)."},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2017.11.012"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0068"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.18553\/jmc2021.27.5.674"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.017"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-1007-x"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.03.021"},{"key":"ref013","unstructured":"United States National Library of Medicine. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ (accessed June 23, 2022)."},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.09.001"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.773629"},{"key":"ref016","unstructured":"United States Food and Drug Administration. Human Gene Therapy for Rare Diseases. Guidance for Industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-rare-diseases (accessed June 15, 2022)."},{"key":"ref017","unstructured":"Official Journal of the European Union. COMMISSION DIRECTIVE 2009\/120\/EC. September 14, 2009. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:9L&from=SL (accessed June 22, 2022)."},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19505-2"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.03.021"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.618346"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2021-0435"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.2022353"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1177\/00469580211059731"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0068"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.04.001"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.200"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307051550"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-012-0004-y"},{"key":"ref029","doi-asserted-by":"crossref","unstructured":"Hughes-WilsonW, PalmaA, SchuurmanA, SimoensS. Paying for the Orphan Drug System: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012;7:74.","DOI":"10.1186\/1750-1172-7-74"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22214"},{"key":"ref031","unstructured":"United States Food and Drug Administration. Approved Cellular and Gene Therapy Products. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapyproducts (accessed June 23, 2022)."},{"key":"ref032","unstructured":"The Paul-Ehrlich-Institut. Gene Therapy Medicinal Products. Available from: https:\/\/www.pei.de\/EN\/medicinalproducts\/atmp\/gene-therapy-medicinal-products\/genetherapy-node.html (accessed June 23, 2022)."},{"key":"ref033","unstructured":"United States Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D. and  Peter Marks, M.D., Ph.D., Director of the Center for  Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. Available from: https:\/\/www.fda.gov\/newsevents\/press-announcements\/statement-fda-commissionerscott-gottlieb-md-and-peter-marks-md-phd-directorcenter-biologics (accessed June 23, 2022)."},{"key":"ref034","unstructured":"United States National Library of Medicine. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ (accessed June 23, 2022)."},{"key":"ref035","unstructured":"United States National Library of Medicine. ClinicalTrials.gov. Phase I\/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A (NCT03520751). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT?term=NCT&draw=2&rank=1 (accessed June 23, 2022)."},{"key":"ref036","unstructured":"World Health Organization. Health technology assessment of medical devices. WHO Medical device technical series. Geneva: WHO Press; 2011."},{"key":"ref037","unstructured":"United States Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). Available from: https:\/\/www.fda.gov\/about-fda\/fda-organization\/center-biologics-evaluation-and-research-cber (accessed June 26, 2022)."},{"key":"ref038","unstructured":"European Medicines Agency. Committee for Advanced Therapies (CAT). Available from: https:\/\/www.ema.europa.eu\/en\/committees\/committee-advanced-therapies-cat (accessed June 26, 2022)."},{"key":"ref039","unstructured":"European Medicines Agency. Orphan designation. Available from: https:\/\/www.ema.europa.eu\/en\/humanregulatory\/overview\/orphan-designation-overview (accessed June 26, 2022)."},{"key":"ref040","unstructured":"United States Food and Drug Administration. Rare Diseases  at FDA. Available from: https:\/\/www.fda.gov\/patients\/rarediseases-fda (accessed June 25, 2022)."},{"key":"ref041","unstructured":"European Medicines Agency. Orphan incentives. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/orphan-designation\/orphanincentives (accessed June 21, 2022)."},{"key":"ref042","unstructured":"United States Food and Drug Administration. Designating an Orphan Product: Drugs and Biological Products. Available from: https:\/\/www.fda.gov\/industry\/developing-products-rare-diseases-conditions\/designating-orphan-product-drugs-and-biological-products (accessed June 22, 851\n2022)."},{"key":"ref043","unstructured":"European Medicines Agency. PRIME: Priority medicines. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines (accessed June 26, 2022)."},{"key":"ref044","unstructured":"United States Food and Drug Administration. Breakthrough Therapy. Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy (accessed June 26, 2022)."},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.11.024"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.12.007"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02388-5"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22390"},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70218-2"},{"key":"ref050","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.05.016"},{"key":"ref051","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70290-9"},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.012"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.3310\/hta2140"},{"key":"ref054","unstructured":"SorensonC, DrummondM, KanavosP. Ensuring value for money in health care: The role of health technology assessment in the European Union. London: European  Observatory for Health Systems and Policies; 2008."},{"key":"ref055","unstructured":"World Health Organization. Health technology assessment  of medical devices. WHO Medical device technical series. Geneva: WHO Press; 2011."},{"issue":"10","key":"ref056","first-page":"1464","volume":"160","author":"Battista R","year":"1999","journal-title":"CMAJ"},{"key":"ref057","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.631527"},{"key":"ref058","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0418-2"},{"key":"ref059","unstructured":"DrummondM, SculpherM, TorranceG, et al. Methods for economic evaluation of health care programmes (4th Edition). Oxford: Oxford University Press; 2015."},{"key":"ref060","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.2002006"},{"key":"ref061","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0672-z"},{"key":"ref062","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1772747"},{"key":"ref063","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01067-w"},{"key":"ref064","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01925-y"},{"key":"ref065","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00323"},{"key":"ref066","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00413-6"},{"key":"ref067","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.026"},{"key":"ref068","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0169"},{"key":"ref069","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.7140"},{"key":"ref070","unstructured":"The United States Centers for Medicare & Medicaid Services. NHE Fact Sheet. Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet (accessed June 25, 2022)."},{"key":"ref071","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00487"},{"key":"ref072","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02022-w"},{"key":"ref073","doi-asserted-by":"publisher","DOI":"10.7399\/fh.11147"},{"key":"ref074","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01718-3"},{"key":"ref075","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.007"},{"key":"ref076","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02260-6"},{"key":"ref077","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02182-3"},{"key":"ref078","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.04.007"},{"key":"ref079","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190451"},{"key":"ref080","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-0998-4"},{"key":"ref081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.12.018"},{"key":"ref082","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1822666"},{"key":"ref083","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01212-w"},{"key":"ref084","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00956-w"},{"key":"ref085","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01147-x"},{"key":"ref086","unstructured":"The Monarch Initiative. Mondo Disease Ontology. Available from: https:\/\/mondo.monarchinitiative.org\/ (accessed June 20, 2022)."},{"key":"ref087","unstructured":"European Medicines Agency. Development of medicines for rare diseases. Available from: https:\/\/www.ema.europa.eu\/en\/news\/development-medicines-rare-diseases (accessed June 26, 2022)."},{"key":"ref088","unstructured":"The United States Food and Drug Administration. Rare Diseases at FDA. Available from: https:\/\/www.fda.gov\/patients\/rare-diseases-fda (accessed June 24, 2022)."},{"key":"ref089","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.11.004"},{"key":"ref090","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01481-9"},{"key":"ref091","unstructured":"GiveWell. How We Produce Impact Estimates. Available from: https:\/\/www.givewell.org\/impact-estimates#footnote121kje50 (accessed June 23, 2022)."},{"key":"ref092","unstructured":"The National Institute for Health and Care Excellence (NICE). Real-world evidence framework. Available from: https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview(accessed June 25, 2022)."},{"key":"ref093","unstructured":"The United States Food and Drug Administration. Framework for FDA\u2019s Real-World Evidence Program. Available from: https:\/\/www.fda.gov\/media\/120060\/download(accessed June 26, 2022)."},{"key":"ref094","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.002"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-221540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-221540","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-221540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:50:03Z","timestamp":1777506603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-221540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["10.3233\/JND-221540"],"URL":"https:\/\/doi.org\/10.3233\/jnd-221540","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}